Teva Pharmaceutical Industries Limited (NYSE:TEVA) Under Analyst Spotlight

What The Copaxone Court Ruling Means For Teva Pharmaceuticals

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Under Analyst Spotlight

Stock performance in last five sessions is recorded as 4.86% while year to date (YTD) performance is 0.33%. Finally, BTIG Research cut Teva Pharmaceutical Industries Limited from a "buy" rating to a "neutral" rating in a research report on Sunday, December 4th. For the current quarter the company has high EPS estimates of $1.44 in contradiction of low EPS estimates of $1.3. Diversified Trust Co's holdings in Teva Pharmaceutical Industries Limited were worth $2,701,000 as of its most recent SEC filing.

01/09/2017 - Teva Pharmaceutical Industries Limited was downgraded to " by analysts at Wells Fargo. The share price of the stock surged 46.57% for the year.

According to consensus agreement of 23 analysts Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) will report earnings per share of $1.36 in their quarterly report and it is expected to announce the company's results on 2/13/17. 23 Analysts think that the Price Target for Teva Pharmaceutical Industries Limited (NYSE:TEVA) might hit $44.7, however, the High Price Target and Low price Target are $80 and $35, respectively.

Analysts await Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) to report earnings on February, 9. Teva Pharmaceutical Industries Limited's dividend payout ratio (DPR) is 67.44%. The company had revenue of $5.56 billion for the quarter, compared to analysts' expectations of $5.71 billion. But the market seems to have already priced that in the company's shares. Hudock Capital Group LLC now owns 2,064 shares of the company's stock worth $103,000 after buying an additional 564 shares during the period. The Corporation has average brokerage recommendation (ABR) of 1.27 based on consensus of the brokerage firms issuing ratings.

Momenta (MNTA) shares also rose thanks to the same litigation with Teva, as Momenta also has a generic version of Copaxone.

Growth Estimate for Teva Pharmaceutical Industries Limited (NYSE:TEVA) is projected at 6.2 percent in the Current Quarter and -3.3 percent in the Next Quarter, according to analysts. The short ratio in the company's stock is documented at 1.86 and the short float is around of 2.01%. The company has grown 15.67% in past 3 months and in the last five trades has moved up 1.8%. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company's stock. If you are reading this news story on another website, it was copied illegally and reposted in violation of worldwide copyright and trademark laws.

12/06/2016 - Teva Pharmaceutical Industries Limited had its " rating reiterated by analysts at Sanford C. Bernstein. 27 Financial Analysts covered the company's stock.

Credit Suisse analyst Vamil Divan said he expects Teva will request a preliminary injunction to prevent the launch of a generic version until legal decisions on all of Teva's outstanding patents are resolved. The Firm operates through two divisions: Generic medicines and Specialty medicines.

Man accused of punching bishop says he's a reverend
Moose falls through window into basement of Idaho home